Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers

Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers &nbsp Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company") has announced an exclusive agreement with Applied Biomedical Science Institute (ABSI) to license technology for human antibodies targeting novel HER2..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 7.
  • textsms

Merck Eyes Keytruda Indication Update with Phase III Gastric Cancer Data

Merck has announced that its blockbuster drug Keytruda met one of its primary endpoints in a Phase III trial for patients with esophageal cancer. The results are an important step toward full approval of the drug for this indication. Merck is now working with the FDA to update the current indication for Keytruda "to those patients whose tumors are PD-L1 positive" following positive results from ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 19.
  • textsms

Astellas Submits New Drug Application for Zolbetuximab in Japan

Japanese pharmaceutical company Astellas Pharma has submitted a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare for zolbetuximab, an investigational Claudin 18.2-targeted monoclonal antibody being evaluated as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tu..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 11.
  • textsms